Supplementary materials of the article
Description
This dataset includes the therapeutic approach distribution among immune checkpoint inhibitor-Induced Bullous pemphigoid subtypes and the initial corticosteroid dosage distribution charts for different subtypes of bullous pemphigoid.
Files
Steps to reproduce
Figure 2: Therapeutic Approach Distribution Among ICI-BP Subtypes Figure Legend: This analysis reveals distinct treatment response profiles across ICI-BP subtypes. The Bullous type showed optimal response to glucocorticoid monotherapy (80% of cases), while the Edematous erythema-bullous type predominantly required combination regimens (55.6% GCs+MTX, 22.2% GCs+MTX+IVIG). The Nodular-erosive type displayed an intermediate pattern, with 75% managed by GCs alone and 25% requiring GCs+MTX+IVIG. Abbreviation: Edematous erythema-bullous type, EEB type; methotrexate,MTX; GCs: Glucocorticoid; IVIG: Intravenous immunoglobulin; Figure 3 (A). Initial Steroid Doses Across Clinical Subtypes (mg) Figure Legend: The analysis revealed significant differences in initial steroid requirements: spontaneous BP (30 mg), Edematous erythema-bullous type (48 mg), Nodular-erosive type (43 mg), and Bullous type (30 mg). (B). Comparison of Initial Steroid Doses Between Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid and Spontaneous Bullous Pemphigoid. Figure Legend: The scatter plot demonstrates significantly higher initial steroid doses in immune-related BP (Edematous erythema-bullous + Nodular-erosive subtypes) versus spontaneous BP (mean methylprednisolone 40 mg vs 30 mg; P=0.0446). Abbreviation：Edematous erythema-bullous type, EEB type